TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01292239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule taken by mouth once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 100-mg capsule taken by mouth once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (pegIFN alfa-2a)
Description: PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (pegIFN alfa-2a)
Description: PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
Study: NCT04279223

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Comparative study to investigate the effect of small-scale trocar use on the development of trocar site hernia in laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Comparative study to investigate the effect of small-scale trocar use on the development of trocar site hernia in laparoscopic cholecystectomy
Study: NCT01834131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Intervention
Description: The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
Study: NCT00262821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirapazamine
Description: Given IV
Study: NCT01789554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLS dispatch for bystander CPR
Study: NCT02680873

Intervention type: OTHER
Group type: OTHER
Intervention: SASI bypass
Description: he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
Study: NCT02199028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: 150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: 150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No hyaluronidase administered into insulin infusion set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No hyaluronidase administered into insulin infusion set.
Study: NCT01832428

Intervention type: OTHER
Group type: OTHER
Intervention: Intra thecal transplantation of Autologous Stem Cells
Description: Intra thecal transplantation of Autologous Stem Cells
Study: NCT03993769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A19010-F
Description: A snus product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A19010-F
Description: A snus product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B19010-F
Description: A snus product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B19010-F
Description: A snus product
Study: NCT03094260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity bright light therapy
Description: Treatment with light therapy in high intensity (10,000 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subject is sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low intensity light therapy
Description: Treatment with light therapy in low intensity (\<500 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subjectis sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position.
Study: NCT03805724

Intervention type: OTHER
Intervention: Plaque Samples
Description: After carefully drying of the selected site and isolation by cotton roll, plaque samples will be collected by sweeping movement of the probe at gingival crevices of the tooth aspect with pervious inclusion criteria for obtaining of the plaque sample. Samples will be immediately dipped in sterile Eppendorf tubes containing PVA.

Intervention type: OTHER
Intervention: Plaque Samples
Description: After carefully drying of the selected site and isolation by cotton roll, plaque samples will be collected by sweeping movement of the probe at gingival crevices of the tooth aspect with pervious inclusion criteria for obtaining of the plaque sample. Samples will be immediately dipped in sterile Eppendorf tubes containing PVA.

Intervention type: OTHER
Intervention: Plaque Samples
Description: After carefully drying of the selected site and isolation by cotton roll, plaque samples will be collected by sweeping movement of the probe at gingival crevices of the tooth aspect with pervious inclusion criteria for obtaining of the plaque sample. Samples will be immediately dipped in sterile Eppendorf tubes containing PVA.
Study: NCT03860233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU administered intranasal, within 1 hour prior to sleeping for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU administered intranasal, within 1 hour prior to sleeping for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal spray to mimic Oxytocin intranasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal spray to mimic Oxytocin intranasal spray
Study: NCT01846182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: serotonin norepinephrine reuptake inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: alpha-2-alpha subunit calcium channel ligand

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01398150

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beverage made to look like the cranberry beverage
Description: one 15 ounce bottle of beverage consumed daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage made from cranberry compounds
Description: one 15 ounce bottle consumed daily for 70 days
Study: NCT01988779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral levofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral levofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized levofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized levofloxacin
Study: NCT01791933

Intervention type: DRUG
Intervention: herbal medicine
Description: 120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months

Intervention type: PROCEDURE
Intervention: Chuna manual therapy
Description: A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion 1-2times a week for more than 2 months Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.

Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture using sterilized disposable needles, sized 0.30X40mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25 ) and other acupoints at physician's discretion, using a total of 10\~20 acupoints 1-2times a week for more than 2 months

Intervention type: PROCEDURE
Intervention: Bee-venom pharmacoacupuncture/pharmacoacupuncture
Description: pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session 1-2times a week for more than 2 months
Study: NCT04072159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Pharmacists Vaccinating Against Cancer
Description: Upon completing informed consent, parents of children who have received Dose 1 of the HPV vaccine at the recent clinical visit will be invited to participate in the study. Upon completing the demographic form and pre-test survey for the study, they will be randomized to intervention or control group. Participants in the intervention group will be asked to complete the additional vaccine doses with their community pharmacist. A provider from the participating clinic will electronically prescribe the HPV vaccine dose. Participants in the control group will be scheduled to return to the clinic (based on the vaccine schedule) to complete the vaccine series. The research team will conduct a follow-up survey six months after baseline for each participant. A sample (n=30) of intervention and control group participants will be invited to participate in an in-depth interview to gauge both parents' and children's' acceptability of this intervention.
Study: NCT04474236

Intervention type: OTHER
Intervention: thoracic lung ultrasound
Description: Patients will be recruited the day of their hospital admission. All patients will be assessed by thoracic Computed Tomography scan then immediately before/after CT scan, patients will be clinically assessed (Q-SOFA, SpiO2/FiO2) and a lung ultrasound evaluation (mean time of evaluation 7 min +/- 3 min; fully respect of COVID-19 barrier measures) will be performed by an investigator. Patients clinical status and outcomes will be extracted from patient's medical file at day 1 and day 28 from patient's admission by investigators blinded from previously recorded lung ultrasound data.
Study: NCT03195192

Intervention type: OTHER
Group type: OTHER
Intervention: biomarker study
Description: This is a biomarker study
Study: NCT02666950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03005470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TELEM
Description: Participants in the telemonitoring home blood pressure (TELEM) group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made early in the morning (5:00 to 10:00) and in the evening (18:00 to 21:00) for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TELEMEV
Description: In the lifestyle telemonitoring group (TELEMEV), participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent out on four of the five days of the week at random times. The messages will be sent to the smarphones through a software developed for this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TELEM-TELEMEV
Description: Participants in the TELEM plus TELEMEV (TELEM-TELEMEV) will receive both interventions as previously described.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UCT
Description: Participants in the control group will receive usual clinical treatment (UCT) on pre-scheduled visits, but will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
Study: NCT00753714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474, Vandetanib
Description: 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match ZD6474, Vandetanib
Description: 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study: NCT02273674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left rTMS 5 Hz
Description: The subjects will receive transcranial magnetic stimulation (5 Hz of frequency over left dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right r TMS 1 Hz
Description: The subjects will receive transcranial magnetic stimulation (1 Hz of frequency over right dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
Study: NCT02701075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MC5-A Scrambler Therapy
Description: up to 10 sessions, each session lasting 30 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MC5-A Scrambler Therapy Sham Device
Description: up to 10 sessions, each session lasting 30 minutes
Study: NCT02234297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ-100
Study: NCT02666950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03104153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early-drain removal
Description: Drain removal at hospital discharge
Study: NCT02788331

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT02666950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WEE1 Inhibitor AZD1775
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WEE1 Inhibitor AZD1775
Description: Given PO
Study: NCT04262544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCardia4HF
Description: Participants in the intervention group will receive the following main components in addition to usual care: 1) the Heart Failure Health Storylines mobile app which supports daily self-monitoring and management of vital signs and symptoms; 2) three connected health devices (Fitbit activity tracker, Withings Cardio Body weight scale and blood pressure monitor), and 3) a program of tailored text-messages targeting health beliefs, self-efficacy, and HF-knowledge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants assigned to the control group will receive usual care and the same connected health devices (Fitbit activity tracker, Withings weight scale and blood pressure monitor) as patients in the intervention group, but without the heart failure health storylines mobile app and text-messaging program. Usual care includes patient education before hospital discharge, and follow-up visits at the outpatient HF clinic a week after discharge and monthly thereafter depending on the patient's condition. Patient education includes literacy-sensitive, education material about HF self-care developed by the Sheps Center for Health Services Research,and a 40-minute education session with an APN and a dietician to review and discuss the education material provided to the patient.
Study: NCT00208416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy MI System
Description: A minimally invasive surgical technique used in total hip replacement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgical technique
Description: A conventional surgical technique used in total hip replacement
Study: NCT02305927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: Supplements containing 3,000 IU vitamin D3 taken orally once per day by the mother starting from the second trimester until 12 months postpartum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplements taken orally once per day by the mother starting from the second trimester until 12 months postpartum
Study: NCT04085783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: Platelet Rich Plasma
Study: NCT00695669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
Study: NCT01657825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: oral
Study: NCT00933621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow intracoronary infusion
Description: Percutaneous intracoronary mononuclear bone marrow cell infusion